-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2109 Unstaged Diffuse Large B Cell Lymphoma in the United States: Predictors and Patient Outcomes

Health Services and Outcomes Research – Malignant Diseases
Program: Oral and Poster Abstracts
Session: 902. Health Services and Outcomes Research – Malignant Diseases: Poster I
Saturday, December 5, 2015, 5:30 PM-7:30 PM
Hall A, Level 2 (Orange County Convention Center)

Binay K. Shah, MD1, Amir Bista, MD2* and Sandhya Sharma, MBBS2

1Cancer Center and Blood Institute, St. Joseph Regional Medical Center, Lewiston, ID
2Guthrie Robert Packer Hospital, Sayre, PA

Background: Treatment and prognosis of diffuse large B cell lymphoma (DLBCL) depends on the stage of lymphoma. We conducted this study to examine unstaged DLBCL in the United States.

Methods and methodology: We used Surveillance Epidemiology and End Result (SEER) 18 registries to select patients with DLBCL diagnosed during January 2000 to December 2012. We used LRD Summary stage 2000 was used to determine stage of the disease - localized, regional, distant or unstaged. We used Logistic regression to investigate factors associated with unstaged DLBCL. We used Cox Proportional Hazard model to compare survival outcomes.

Results: Among 67765 patients, 3194 (4.71%) were unstaged. Age (60+years), "Others" and Caucasian races, single or single/divorced/widow marital status, metropolitan residence, median household income> $50,000, lymph node as the primary site and cased with other primaries before diagnosis of DLBCL were the factors associated with unstaged cases (Table 1). The 5- year relative survival rate for unstaged patients was inferior to those with localized and regional disease, and superior to those with distant disease (HRs of 0.58, 0.66 and 1.24 for localized, regional and distant respectively when compared to unstaged cases). 

Conclusion: In this large population-based study, 4.71% patients with DLBCL had unstaged disease. Patients with unstaged DLBC had significantly inferior survival rates compared to patients with localized and regional stage.

Table 1: Factors associated with unstaged DLBCL cases:

Parameters

Unadjusted OR ( 95% CI)

P value

Adjusted OR ( 95% CI)

P value

Age ( 60+ Vs. <60 years)

1.478 (1.363 – 1.602)

<0.001

1.458 (1.335 – 1.592)

<0.001

Sex (Female Vs. Male)

1.063 (0.990 – 1.141)

0.093

0.983 (0.911 – 1.059)

0.646

Race

Caucasians

Reference

Reference

African American

0.804 (0.691 – 0.935)

0.005

0.835 (0.715 – 0.974)

0.022

Others

1.109 (0.976 – 1.261)

0.112

1.257 (1.104 – 1.431)

0.001

Marital Status

Married

Reference

Reference

Single

1.026 (0.927 – 1.135)

0.662

1.208 (1.086 – 1.345)

0.001

Single/divorced/widow

1.249 (1.152 – 1.355)

<0.001

1.185 (1.087 – 1.291)

<0.001

Rural/Urban

Rural

Reference

Reference

Urban

0.878 (0.651 – 1.183)

0.393

0.896 (0.661 – 1.214)

0.479

Metropolitan

0.882 (0.667 – 1.165)

0.882

1.028 (0.767 – 1.379)

0.852

Median annual household income

Upto 25,000

Reference

Reference

>25,000-50,000

01.009 (0.753 – 1.354)

0.951

0.927 (0.675 – 1.271)

0.636

>50,000

0.758 (0.563 – 1.021)

0.068

0.673 (0.486 – 0.933)

0.017

Sequence (Not first or only primary vs. first or only primary)

1.261 (1.156 – 1.377)

<0.001

1.219 (1.115 – 1.334)

<0.001

Site of primary

Lymph nodes

Reference

Reference

Extra-lymphatic

0.760 (0.704 – 0.821)

<0.001

0.748 (0.693 – 0.808)

<0.001

Unknown primary

6.295 (4.569 – 8.672)

<0.001

6.727 (4.865 – 9.300)

<0.001

Disclosures: No relevant conflicts of interest to declare.

*signifies non-member of ASH